Study and results
Sixty adults with inadequately controlled type 2 diabetes were recruited to receive ginkgo extract or placebo alongside metformin for ninety days. Only twenty placebo and twenty-seven ginkgo participants completed and entered the final analysis. [1]
Several measures improved from baseline in the ginkgo group. However, improvement in one group and nonsignificant change in another do not alone prove a treatment difference; insulin was explicitly not significantly different between groups at the end. [1]
Interpretation and limitations
The university provided support and facilities, and authors declared no conflicts. Attrition and the analysis approach warrant caution. This study does not establish that ginkgo should replace or routinely supplement prescribed diabetes treatment. [1]
A hypothetical distinction
Imagine one group has a statistically significant baseline change and another does not. A direct comparison of changes is still required to establish that the effects differ.
| Detail | Interpretation |
|---|---|
| Within-group change | Different statistical question |
| Dropout | Can bias the analyzed sample |
| Routine adjunct use | Not established here |
Sources for this article
- The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial - PMC
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.